Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients.

Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients. Abstract Text:

Hong Xu,Paula M Chilton,Michael K Tanner,Yiming Huang,Carrie L Schanie,Mariano Dy-Liacco,Jun Yan,Suzanne T Ildstad,

We evaluated the relative contribution of the humoral and cellular arms of the immune response to bone marrow cells transplanted into sensitized recipients. We report here for the first time that humoral immunity contributes predominantly to allosensitization. Although the major role for nonmyeloablative conditioning is to control alloreactive host T cells in nonsensitized recipients, strikingly, none of the strategies directed primarily at T-cell alloreactivity enhanced engraftment in sensitized mice. In evaluating the mechanism behind this barrier, we found that humoral immunity plays a critical role in the rejection of allogeneic marrow in sensitized recipients. Adoptive transfer of as little as 25 microL serum from sensitized mice abrogated engraftment in secondary naive recipients. With the use of microMT mice as recipients, we found that T-cell-mediated immunity plays a secondary but still significant role in allorejection. Targeting of T cells in sensitized B-cell-deficient microMT mice enhanced alloengraftment. Moreover, both T- and B-cell tolerance were achieved in sensitized recipients when allochimerism was established, as evidenced by the acceptance of second donor skin grafts and loss of circulating donor-specific Abs. These findings have important implications for the management of sensitized transplant recipients and for xenotransplantation in which B-cell reactivity is a predominant barrier.

Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients. Publishing Authors By Initials

H Xu,PM Chilton,MK Tanner,Y Huang,CL Schanie,M Dy-Liacco,J Yan,ST Ildstad,

For similar surgical procedures, operative: transplantation: transplantation, homologous research abstracts see: surgical procedures, operative: transplantation: transplantation, homologous research

PUBMED ID PMID:

MEDLINE DATE:

Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Blood

VOLUME: 108

Page Numbers: 3611-9

Journal Abbreviation: Blood

ISSN: 0006-4971

DAY: 3

MONTH: 08

YEAR: 2006

Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7603509

Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients. Keywords Mesh Terms:

KEYWORDS: Transplantation, Homologous

MESH TERMS: immunology

Chemical & Substance for Abstract: Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients.

AFFILIATION: Institute for Cellular Therapeutics, Ste 404, University of Louisville, 570 S Preston St, Louisville, KY 40202-1760, USA.

Country: United States

AGENCY: United States NHLBI

GRANT: R01 HL63442

ACRONYM: HL

MEDLINETA: Blood

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients Related Publications

• A modified model of hindlimb osteomyocutaneous flap for the study of tolerance to composite tissue allografts.
• Addition of cyclophosphamide to T-cell depletion-based nonmyeloablative conditioning allows donor T-cell engraftment and clonal deletion of alloreactive host T-cells after bone marrow transplantation.
• Coexpression of NKR-P1 and alpha beta-TCR on lymphoid cells in fully xenogeneic (rat-->mouse) chimeras and syngeneically reconstituted (A-->A) rats.
• Composite tissue transplantation: a rapidly advancing field.
• Costimulatory blockade of CD154-CD40 in combination with T-cell lymphodepletion results in prevention of allogeneic sensitization.
• Facilitating cells: novel promoters of stem cell alloengraftment and donor-specific transplantation tolerance in the absence of GVHD.
• Fms-related tyrosine kinase 3 expression discriminates hematopoietic stem cells subpopulations with differing engraftment-potential: identifying the most potent combination.
• Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients.
• NK cells play a critical role in the regulation of class I-deficient hemopoietic stem cell engraftment: evidence for NK tolerance correlates with receptor editing.
• Plasmacytoid precursor dendritic cells from NOD mice exhibit impaired function: are they a component of diabetes pathogenesis?
• Preferential development of NKR-P1-expressing cells in the spleen versus thymus and bone marrow of fully xenogeneic (rat-->mouse) chimeras.
• Science of composite tissue allotransplantation.
• TNF-{alpha} Is Critical to Facilitate Hemopoietic Stem Cell Engraftment and Function.